Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | MicrobiomeTrials← Back to trialsNCT05489549
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
RecruitingOBSERVATIONAL
Trial Details
Start: 2022-11-21Est. Completion: 2027-06-30
Enrollment target: 500 participants Locations- Columbia University Medical Center, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Other microbiome trials you might be interested in
Cardiac Amyloidosis
Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired…
Dijon, FranceEst. completion Jul 2028
Cardiac AmyloidosisHeart Failure With Preserved Ejection Fraction (HFPEF)Left Ventricular Hypertrophy
Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure s…
Multiple LocationsEst. completion Apr 2028